These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
117 related articles for article (PubMed ID: 35397393)
21. Adverse cutaneous toxicities by PD-1/PD-L1 immune checkpoint inhibitors: pathogenesis, treatment, and surveillance. Bhardwaj M; Chiu MN; Pilkhwal Sah S Cutan Ocul Toxicol; 2022 Mar; 41(1):73-90. PubMed ID: 35107396 [TBL] [Abstract][Full Text] [Related]
22. Patterns of immunotherapy use and management of toxicities in regional and tertiary settings. Hamilton B; Xu K; Honeyball F; Balakrishnar B; Zielinski R Intern Med J; 2019 Aug; 49(8):1010-1015. PubMed ID: 30693623 [TBL] [Abstract][Full Text] [Related]
23. Ramucirumab plus pembrolizumab in patients with previously treated advanced non-small-cell lung cancer, gastro-oesophageal cancer, or urothelial carcinomas (JVDF): a multicohort, non-randomised, open-label, phase 1a/b trial. Herbst RS; Arkenau HT; Santana-Davila R; Calvo E; Paz-Ares L; Cassier PA; Bendell J; Penel N; Krebs MG; Martin-Liberal J; Isambert N; Soriano A; Wermke M; Cultrera J; Gao L; Widau RC; Mi G; Jin J; Ferry D; Fuchs CS; Petrylak DP; Chau I Lancet Oncol; 2019 Aug; 20(8):1109-1123. PubMed ID: 31301962 [TBL] [Abstract][Full Text] [Related]
24. Anti-programmed cell death-1 and anti-programmed cell death ligand-1 immune-related liver diseases: from clinical pivotal studies to real-life experience. Vitale G; Lamberti G; Comito F; Di Nunno V; Massari F; Morelli MC; Ardizzoni A; Gelsomino F Expert Opin Biol Ther; 2020 Sep; 20(9):1047-1059. PubMed ID: 32425081 [TBL] [Abstract][Full Text] [Related]
25. Endocrine toxicity in cancer patients treated with nivolumab or pembrolizumab: results of a large multicentre study. Presotto EM; Rastrelli G; Desideri I; Scotti V; Gunnella S; Pimpinelli N; Vaccher E; Bearz A; Di Costanzo F; Bruggia M; Mini E; Maggi M; Peri A J Endocrinol Invest; 2020 Mar; 43(3):337-345. PubMed ID: 31542865 [TBL] [Abstract][Full Text] [Related]
26. Clinical Outcomes of Metastatic Renal Carcinoma Following Disease Progression to Programmed Death (PD)-1 or PD-L1 Inhibitors (IO): A Meet-URO Group Real World Study (Meet-Uro 7). Santini D; Stellato M; De Giorgi U; Pantano F; De Lisi D; Casadei C; Maruzzo M; Bimbatti D; Naglieri E; Buti S; Bersanelli M; De Vivo R; Di Lorenzo G; Sbrana A; Verzoni E; Soraru' M; Fornarini G; Mucciarini C; Grillone F; Mini E; Vignani F; Attademo L; Pignata S; Procopio G Am J Clin Oncol; 2021 Mar; 44(3):121-125. PubMed ID: 33617179 [TBL] [Abstract][Full Text] [Related]
27. Analysis of Real-World Data to Investigate the Impact of Race and Ethnicity on Response to Programmed Cell Death-1 and Programmed Cell Death-Ligand 1 Inhibitors in Advanced Non-Small Cell Lung Cancers. Ayers KL; Mullaney T; Zhou X; Liu JJ; Lee K; Ma M; Jones S; Li L; Redfern A; Jappe W; Liu Z; Goldsweig H; Yadav KK; Hahner N; Dietz M; Zimmerman M; Prentice T; Newman S; Veluswamy R; Wisnivesky J; Hirsch FR; Oh WK; Li SD; Schadt EE; Chen R Oncologist; 2021 Jul; 26(7):e1226-e1239. PubMed ID: 33829580 [TBL] [Abstract][Full Text] [Related]
28. Adverse Event Management in Patients with Chalmers A; Cannon L; Akerley W Oncologist; 2019 Jul; 24(7):963-972. PubMed ID: 30598499 [TBL] [Abstract][Full Text] [Related]
29. Late-onset and long-lasting immune-related adverse events from immune checkpoint-inhibitors: An overlooked aspect in immunotherapy. Ghisoni E; Wicky A; Bouchaab H; Imbimbo M; Delyon J; Gautron Moura B; Gérard CL; Latifyan S; Özdemir BC; Caikovski M; Pradervand S; Tavazzi E; Gatta R; Marandino L; Valabrega G; Aglietta M; Obeid M; Homicsko K; Mederos Alfonso NN; Zimmermann S; Coukos G; Peters S; Cuendet MA; Di Maio M; Michielin O Eur J Cancer; 2021 May; 149():153-164. PubMed ID: 33865201 [TBL] [Abstract][Full Text] [Related]
30. Side Effects and Efficacy of Immunotherapy. Fiala O; Šorejs O; Šustr J; Fínek J Klin Onkol; 2020; 33(1):8-10. PubMed ID: 32075381 [TBL] [Abstract][Full Text] [Related]
31. Cardiovascular adverse events are associated with usage of immune checkpoint inhibitors in real-world clinical data across the United States. Jain P; Gutierrez Bugarin J; Guha A; Jain C; Patil N; Shen T; Stanevich I; Nikore V; Margolin K; Ernstoff M; Velcheti V; Barnholtz-Sloan J; Dowlati A ESMO Open; 2021 Oct; 6(5):100252. PubMed ID: 34461483 [TBL] [Abstract][Full Text] [Related]
32. [Real-world study on the efficacy and prognostic predictive biomarker of patients with metastatic non-small cell lung cancer treated with programmed death-1/programmed death ligand 1 inhibitors]. Zhu WJ; Zhu HH; Liu YT; Lin L; Xing PY; Hao XZ; Cong MH; Wang HY; Wang Y; Li JL; Feng Y; Hu XS Zhonghua Zhong Liu Za Zhi; 2022 May; 44(5):416-424. PubMed ID: 35615798 [No Abstract] [Full Text] [Related]
33. Clinical characteristics of gastrointestinal immune-related adverse events of immune checkpoint inhibitors and their association with survival. Yamada K; Sawada T; Nakamura M; Yamamura T; Maeda K; Ishikawa E; Iida T; Mizutani Y; Kakushima N; Ishikawa T; Furukawa K; Ohno E; Honda T; Kawashima H; Ishigami M; Furune S; Hase T; Yokota K; Maeda O; Hashimoto N; Akiyama M; Ando Y; Fujishiro M World J Gastroenterol; 2021 Nov; 27(41):7190-7206. PubMed ID: 34887637 [TBL] [Abstract][Full Text] [Related]
34. Safety of current immune checkpoint inhibitors in non-small cell lung cancer. Abdayem P; Planchard D Expert Opin Drug Saf; 2021 Jun; 20(6):651-667. PubMed ID: 33393387 [No Abstract] [Full Text] [Related]
35. Comparison of the toxicity profile of PD-1 versus PD-L1 inhibitors in non-small cell lung cancer: A systematic analysis of the literature. Pillai RN; Behera M; Owonikoko TK; Kamphorst AO; Pakkala S; Belani CP; Khuri FR; Ahmed R; Ramalingam SS Cancer; 2018 Jan; 124(2):271-277. PubMed ID: 28960263 [TBL] [Abstract][Full Text] [Related]
36. Safety of Immune Checkpoint Inhibitors in Patients with Cancer and Hepatitis C Virus Infection. Alkrekshi A; Tamaskar I Oncologist; 2021 May; 26(5):e827-e830. PubMed ID: 33655663 [TBL] [Abstract][Full Text] [Related]
37. Immune-related adverse events with immune checkpoint inhibitors affecting the skeleton: a seminal case series. Moseley KF; Naidoo J; Bingham CO; Carducci MA; Forde PM; Gibney GT; Lipson EJ; Shah AA; Sharfman WH; Cappelli LC J Immunother Cancer; 2018 Oct; 6(1):104. PubMed ID: 30305172 [TBL] [Abstract][Full Text] [Related]
38. Are immune checkpoint inhibitors a valid option for papillary renal cell carcinoma? A multicentre retrospective study. de Vries-Brilland M; Gross-Goupil M; Seegers V; Boughalem E; Beuselinck B; Thibault C; Chevreau C; Ladoire S; Barthélémy P; Negrier S; Borchiellini D; Huillard O; Geoffrois L; Gravis G; Saldana C; Thiery-Vuillemin A; Escudier B; Ravaud A; Albiges L Eur J Cancer; 2020 Sep; 136():76-83. PubMed ID: 32653774 [TBL] [Abstract][Full Text] [Related]
39. Safety and tolerability of PD-1/PD-L1 inhibitors in the treatment of non-small cell lung cancer: a meta-analysis of randomized controlled trials. Luo W; Wang Z; Tian P; Li W J Cancer Res Clin Oncol; 2018 Oct; 144(10):1851-1859. PubMed ID: 30019319 [TBL] [Abstract][Full Text] [Related]
40. Machine learning for prediction of cutaneous adverse events in patients receiving anti-PD-1 immunotherapy. Lewinson RT; Meyers DE; Vallerand IA; Suo A; Dean ML; Cheng T; Bebb DG; Morris DG J Am Acad Dermatol; 2021 Jan; 84(1):183-185. PubMed ID: 32334053 [No Abstract] [Full Text] [Related] [Previous] [Next] [New Search]